The Recombinant Protein Expression and Purification (RPrEP) Core was launched in 2009 to provide a cost-effective resource to the DF/HCC community for expression and purification of recombinant fusion proteins necessary for pre-clinical studies as well as for basic mechanistic studies by immunologists and cancer biologists

The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research

The Community Practice Core (CPC) offers access to a clinical laboratory of over ten million patients within Harvard Vanguard Medical Associates, Harvard Pilgrim Health Care, and the HMO Cancer Research Network

Twelve individuals have recently joined DF/HCC

Acute myelogenous leukemia (AML), a disease for which treatment has remained relatively unchanged for the past 30 years, is the subject of a new clinical trial featuring a drug aimed at boosting the efficacy of standard induction chemotherapy

Based largely on original research from a team of DF/HCC investigators, a new clinical trial has launched to determine if combination therapy with a tyrosine kinase inhibitor (neratinib) in combination with an mTOR inhibitor (temsirolimus, Torisel®) can more effectively shut down an important signaling pathway involved in solid tumors like lung and breast cancers

The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient pool exists to conduct clinical testing in a timely way